Uncategorized

FluoGuide receives FDA Orphan Drug Designation for FG001 in High-Grade Glioma

Copenhagen, Denmark – FluoGuide A/S, a pioneer in the cutting-edge field of precision cancer surgery, is pleased to announce its lead asset FG001 has received Orphan Drug Designation from the U. S. Food and Drug Administration as an optical imaging agent for the visualization of malignant tissue during surgery for high-grade glioma.

FluoGuide receives FDA Orphan Drug Designation for FG001 in High-Grade Glioma Read More »

Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli

Sanofi announces that it has entered into an agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E.coli developed by Janssen, currently in Phase 3.

Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli Read More »

Scroll to Top